SEARCH

SEARCH BY CITATION

References

  • 1
    Itoh, N. & Ornitz, D.M. (2004) Evolution of the Fgf and Fgfr gene families. Trends in Genetics, 20, 563569.
  • 2
    Kharitonenkov, A. (2009) FGFs and metabolism. Current Opinion in Pharmacology, 9, 805810.
  • 3
    Nishimura, T., Nakatake, Y., Konishi, M. et al. (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochimica et Biophysica Acta, 1492, 203206.
  • 4
    Fon Tacer, K., Bookout, A.L., Ding, X. et al. (2010) Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Molecular Endocrinology, 24, 20502064.
  • 5
    Inagaki, T., Dutchak, P., Zhao, G. et al. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism, 5, 415425.
  • 6
    Dutchak, P.A., Katafuchi, T., Bookout, A.L. et al. (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell, 148, 556567.
  • 7
    Kharitonenkov, A., Shiyanova, T.L., Koester, A. et al. (2005) FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation, 115, 16271635.
  • 8
    Kharitonenkov, A., Wroblewski, V.J., Koester, A. et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 148, 774781.
  • 9
    Huang, X., Yu, C., Jin, C. et al. (2006) Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Molecular Carcinogenesis, 45, 934942.
  • 10
    Zhang, X., Yeung, D.C., Karpisek, M. et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57, 12461253.
  • 11
    Chen, C., Cheung, B.M., Tso, A.W. et al. (2011) High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5·4-year population-based prospective study in Chinese subjects. Diabetes Care, 34, 21132115.
  • 12
    Fisher, F.M., Chui, P.C., Antonellis, P.J. et al. (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes, 59, 27812789.
  • 13
    Badman, M.K., Pissios, P., Kennedy, A.R. et al. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism, 5, 426437.
  • 14
    Lundasen, T., Hunt, M.C., Nilsson, L.M. et al. (2007) PPARalpha is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications, 360, 437440.
  • 15
    Hondares, E., Iglesias, R., Giralt, A. et al. (2011) Thermogenic activation induces FGF21 expression and release in brown adipose tissue. Journal of Biological Chemistry, 286, 1298312990.
  • 16
    Galman, C., Lundasen, T., Kharitonenkov, A. et al. (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metabolism, 8, 169174.
  • 17
    Uebanso, T., Taketani, Y., Yamamoto, H. et al. (2011) Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor? PLoS ONE, 6, e22976.
  • 18
    Mraz, M., Bartlova, M., Lacinova, Z. et al. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clinical endocrinology (Oxford), 71, 369375.
  • 19
    Berglund, E.D., Li, C.Y., Bina, H.A. et al. (2009) Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology, 150, 40844093.
  • 20
    Sarruf, D.A., Thaler, J.P., Morton, G.J. et al. (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes, 59, 18171824.
  • 21
    Hsuchou, H., Pan, W. & Kastin, A.J. (2007) The fasting polypeptide FGF21 can enter brain from blood. Peptides, 28, 23822386.
  • 22
    Kharitonenkov, A., Dunbar, J.D., Bina, H.A. et al. (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. Journal of Cellular Physiology, 215, 17.
  • 23
    Wente, W., Efanov, A.M., Brenner, M. et al. (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes, 55, 24702478.
  • 24
    Moyers, J.S., Shiyanova, T.L., Mehrbod, F. et al. (2007) Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. Journal of Cellular Physiology, 210, 16.
  • 25
    Potthoff, M.J., Inagaki, T., Satapati, S. et al. (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. The Proceedings of the National Academy of Sciences USA, 106, 1085310858.
  • 26
    Fisher, F.M., Estall, J.L., Adams, A.C. et al. (2011) Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology, 152, 29963004.
  • 27
    Badman, M.K., Koester, A., Flier, J.S. et al. (2009) Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology, 150, 49314940.
  • 28
    Hotta, Y., Nakamura, H., Konishi, M. et al. (2009) Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology, 150, 46254633.
  • 29
    Dushay, J., Chui, P.C., Gopalakrishnan, G.S. et al. (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology, 139, 456463.
  • 30
    Chen, W., Hoo, R.L., Konishi, M. et al. (2011) Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. Journal of Biological Chemistry, 286, 3455934566.
  • 31
    Arner, P., Pettersson, A., Mitchell, P.J. et al. (2008) FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Letters, 582, 17251730.
  • 32
    Yu, H., Xia, F., Lam, K.S. et al. (2011) Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clinical Chemistry, 57, 691700.
  • 33
    Xu, J., Lloyd, D.J., Hale, C. et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes, 58, 250259.
  • 34
    Reinehr, T., Woelfle, J., Wunsch, R. et al. (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. Journal of Clinical Endocrinology and Metabolism, 97, 214350.
  • 35
    Mai, K., Andres, J., Biedasek, K. et al. (2009) Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes, 58, 15321538.
  • 36
    Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A. et al. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care, 32, 15421546.
  • 37
    Yang, M., Dong, J., Liu, H. et al. (2011) Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS ONE, 6, e26359.
  • 38
    Lin, Z., Wu, Z., Yin, X. et al. (2010) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE, 5, e15534.
  • 39
    Li, H., Fang, Q., Gao, F. et al. (2010) Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology, 53, 934940.
  • 40
    Gorar, S., Culha, C., Uc, Z.A. et al. (2010) Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecological Endocrinology, 26, 819826.
  • 41
    Diaz-Delfin, J., Hondares, E., Iglesias, R. et al. (2012) TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells; involvement of JNK1 in the FGF21 pathway. Endocrinology, 153, 42384245.
  • 42
    Dostalova, I., Kavalkova, P., Haluzikova, D. et al. (2008) Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism, 93, 36273632.
  • 43
    Fazeli, P.K., Misra, M., Goldstein, M. et al. (2010) Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism, 95, 369374.
  • 44
    Inagaki, T., Lin, V.Y., Goetz, R. et al. (2008) Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metabolism, 8, 7783.
  • 45
    Xiao, Y., Xu, A., Law, L.S. et al. (2012) Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. Journal of Clinical Endocrinology and Metabolism, 97, E5458.
  • 46
    Johnson, C.L., Weston, J.Y., Chadi, S.A. et al. (2009) Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology, 137, 17951804.
  • 47
    Stein, S., Bachmann, A., Lossner, U. et al. (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care, 32, 126128.
  • 48
    Lin, Z., Zhou, Z., Liu, Y. et al. (2011) Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE, 6, e18398.
  • 49
    Jian, W.X., Peng, W.H., Jin, J. et al. (2012) Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism, 61, 853859.
  • 50
    Li, K., Li, L., Yang, M. et al. (2009) Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. European Journal of Endocrinology, 161, 391395.
  • 51
    Durovcova, V., Marek, J., Hana, V. et al. (2010) Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome. Physiological Research, 59, 415422.
  • 52
    Lin, Z., Gong, Q., Wu, C. et al. (2012) Dynamic change of serum FGF21 levels in response to glucose challenge in human. Journal of Clinical Endocrinology and Metabolism, 97, E12241228.
  • 53
    Semba, R.D., Sun, K., Egan, J.M. et al. (2012) Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. Journal of Clinical Endocrinology and Metabolism, 97, 13751382.
  • 54
    Coskun, T., Bina, H.A., Schneider, M.A. et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 149, 60186027.
  • 55
    Mu, J., Pinkstaff, J., Li, Z. et al. (2012) FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes, 61, 505512.
  • 56
    Wei, W., Dutchak, P.A., Wang, X. et al. (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. The Proceedings of the National Academy of Sciences USA, 109, 31433148.